Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Sponsor

University of Washington (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05453396

Collaborator

(none)

Enrollment

Location

Arm

42.1

Anticipated Duration (Months)

0.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This phase II trial tests whether loncastuximab tesirine works to shrink tumors in patients with B-cell malignancies that have come back (relapsed) or does not respond to treatment (refractory). Loncastuximab tesirine is a monoclonal antibody, called loncastuximab, linked to a chemotherapy drug, called tesirine. Loncastuximab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD19 receptors, and delivers tesirine to kill them.

Condition or Disease	Intervention/Treatment	Phase
Post-Transplant Lymphoproliferative Disorder Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Neoplastic Post-Transplant Lymphoproliferative Disorder Refractory B-Cell Non-Hodgkin Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Follicular Lymphoma Refractory Mantle Cell Lymphoma Refractory Neoplastic Post-Transplant Lymphoproliferative Disorder	Biological: Loncastuximab Tesirine	Phase 2

Detailed Description

OUTLINE:

Patients receive loncastuximab tesirine intravenously (IV) over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 5 years.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

40 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Pilot Study of Loncastuximab Tesirine in Specific Populations of Relapsed/Refractory B-Cell Malignancies

Anticipated Study Start Date :

Jan 1, 2023

Anticipated Primary Completion Date :

Dec 15, 2025

Anticipated Study Completion Date :

Jul 6, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment (loncastuximab tesirine) Patients receive loncastuximab tesirine IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.	Biological: Loncastuximab Tesirine Given IV Other Names: ADC ADCT-402 ADCT-402 Anti-CD19 PBD-conjugate ADCT-402 Loncastuximab Tesirine-lpyl Zynlonta

Arm

Intervention/Treatment

Experimental: Treatment (loncastuximab tesirine)

Patients receive loncastuximab tesirine IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.

Biological: Loncastuximab Tesirine

Given IV

Other Names:

ADC ADCT-402

ADCT-402

Anti-CD19 PBD-conjugate ADCT-402

Loncastuximab Tesirine-lpyl

Zynlonta

Outcome Measures

Primary Outcome Measures

Overall response rate (ORR) [Up to 5 years]
According to the 2014 Lugano classification Cheson 20146 as determined by local review; ORR is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR).

Secondary Outcome Measures

Rates of grade 3-5 adverse event [Up until 30 days after the last dose of the last study drug]
Rate of discontinuation due to adverse events [Up until 30 days after the last dose of the last study drug]
Clinical benefit rate [Up to 5 years]
Defined as stable disease + partial or complete response.
Duration or response [Time from the first documentation of tumor response to disease progression or death, assessed up to 5 years]
Progression free survival [Time between start of treatment and the first documentation of recurrence, progression, or death, assessed up to 5 years]
Overall survival [Time between the start of treatment and death from any cause, assessed up to 5 years]
Incidence of grade 3-5 drug-related toxicity [Up until 30 days after the last dose of the last study drug]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male or female patient aged 18 years or older
Disease-specific criteria:
Group 1: CD19+ relapsed/refractory post-transplant lymphoproliferative disorder (PTLD),
Group 2: Relapsed/refractory. CD19+ B-cell non-Hodgkin lymphoma (B-NHL) excluding Waldenstrom's macroglobulinemia and marginal zone lymphoma, (at least 1 prior therapy, and no alternative with a more favorable benefit/risk ratio in the judgment of the treating investigator.
Group 3: CD19+ diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or mantle cell lymphoma (MCL) relapsing after chimeric antigen receptor (CAR) T-cell therapy or allogeneic transplant (at least 30 days from CAR T/transplant)
Group 4: Relapsed/refractory, CD19-negative B-NHL by both immunohistochemistry and flow cytometry (minimal to absent expression). Patients (Pts) must have had at least 1 prior therapy, and no alternative with a more favorable benefit/risk ratio in the judgment of the treating investigator
Have measurable nodal or extranodal disease, including at least 1 disease site measuring 1.5 cm in longest dimension; or splenomegaly; or histologic marrow involvement for marrow-only presentations
Have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance scale (PS)
Absolute neutrophil count (ANC) >= 1.0 x 10^{3/uL (off growth factors at least 72
hours), unless due to marrow involvement by lymphoma in which case ANC must be >= 0.5
x 10}3/uL
Platelet count >= 75 x 10^{3/uL without transfusion in the prior 7 days, unless due to
disease including splenomegaly in which case platelet count must be >= 50 x 10}3/uL
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma glutamyl transferase (GGT) =< 3 x the upper limit of normal (ULN)
Total bilirubin =< 1.5 x ULN (patients with known Gilbert's syndrome may have a total bilirubin up to =< 3 x ULN)
Blood creatinine =< 2.0 x ULN or calculated creatinine clearance >= 50 mL/min by the Cockcroft and Gault equation
Negative beta-human chorionic gonadotropin (beta-HCG) pregnancy test within 7 days prior to start of study drug (cycle 1 day 1 [C1D1]) for women of childbearing potential
Women of childbearing potential must agree to use a highly effective method of contraception from the time of giving informed consent until at least 9 months after the last dose of loncastuximab tesirine
Men with female partners who are of childbearing potential must agree that they will use a condom from the time of giving informed consent until at least 6 months after the patient receives his last dose of loncastuximab tesirine

Exclusion Criteria:

Previous treatment with loncastuximab tesirine
Known history of hypersensitivity to loncastuximab tesirine
Active second primary malignancy other than non-melanoma skin cancers, non-metastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy
Uncontrolled graft-versus-host disease
Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive or hepatitis B virus [HBV] deoxyribonucleic acid [DNA] detectable) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)
Is pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 9 months after the last dose of trial treatment
Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath)
Lymphoma with active central nervous system (CNS) involvement at the time of screening, including active leptomeningeal disease. A history of treated CNS disease permitted
Significant medical comorbidities, including but not limited to unstable angina, congestive heart failure (New York Heart Association class III or greater), uncontrolled atrial or ventricular cardiac arrhythmia, that would, in the Investigator's judgment, make the patient inappropriate for study participation or put the patient at risk
Major surgery, radiotherapy, chemotherapy or other anti-neoplastic therapy within 14 days prior to start of study drug (C1D1)
Use of any other experimental medication within 14 days prior to start of study drug (C1D1)
Planned live vaccine administration after starting study drug (C1D1)
Any other significant medical illness, abnormality, or condition that would, in the investigator's judgment, make the patient inappropriate for study participation or put the patient at risk
Is currently participating in a study and receiving an investigational agent or is using an investigational device within 4 weeks of the first dose of treatment